A kind of pharmaceutical composition for preventing and/or treating cardiomyopathy and nephropathy and its preparation method and application
A composition and drug technology, applied in the field of biomedicine, to achieve the effects of improving left ventricular systolic and diastolic function, reducing myocardial fibrosis and reducing urinary protein
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0046] In another specific embodiment of the present invention, there is provided a preparation method of the above-mentioned nanoparticles, the preparation method comprising:
[0047] S1, chitosan is dissolved in glacial acetic acid solution, adjust pH with saturated sodium hydroxide solution, obtain solution I;
[0048] S2, adding the Ang IV polypeptide into the sodium tripolyphosphate (TPP) aqueous solution to dissolve, adding the Ang IV polypeptide and the sodium tripolyphosphate mixed solution dropwise to the above solution I, and forming nanoparticles spontaneously by the electrostatic action of anions and cations; Wash and freeze-dry.
[0049] In another specific embodiment of the present invention, the molecular weight of chitosan is 200-2000kDa, more preferably 250-1200kDa, most preferably 600kDa, and the degree of deacetylation is greater than 90%.
[0050] In another specific embodiment of the present invention, in step S1, the pH value is adjusted to 4.5-6.0, pref...
Embodiment 1
[0062] Embodiment 1 A kind of pharmaceutical composition for treating and / or preventing cardiomyopathy and nephropathy
[0063] The pharmaceutical composition is chitosan nanoparticles encapsulating Ang IV polypeptide.
[0064] The preparation method of the chitosan nanoparticles encapsulating the Ang IV polypeptide, comprising the following steps:
[0065] (1) 30 mg of chitosan with a molecular weight of 600 kDa was dissolved in 8 mL of 10% glacial acetic acid solution, and the pH was adjusted to 5.5 with saturated sodium hydroxide solution to obtain solution I;
[0066] (2) Take 2 mL of Ang IV polypeptide solution with a concentration of 1.5 μmol / dL and 2 mL of 0.5 mg / mL sodium tripolyphosphate (TPP) aqueous solution and mix and stir (1000 rpm) evenly. Mix 1 drop of Ang IV polypeptide and TPP solution. It is added dropwise into the above solution I at a speed of / 3 to 5 seconds, and nanoparticles are formed spontaneously through the electrostatic action of anions and cation...
Embodiment 2
[0067] Embodiment 2 A kind of pharmaceutical composition for treating and / or preventing cardiomyopathy and nephropathy
[0068] The pharmaceutical composition is chitosan nanoparticles encapsulating Ang IV polypeptide.
[0069] The preparation method of the chitosan nanoparticles encapsulating the Ang IV polypeptide, comprising the following steps:
[0070] (1) 10 mg of chitosan with a molecular weight of 250 kDa was dissolved in 8 mL of 10% glacial acetic acid solution, and the pH was adjusted to 5.5 with saturated sodium hydroxide solution to obtain solution I;
[0071] (2) Take 2 mL of Ang IV polypeptide solution with a concentration of 1.5 μmol / dL and 2 mL of 0.5 mg / mL TPP aqueous solution and mix and stir (1000 rpm) evenly. Speed dropwise added to the above solution I, through the electrostatic action of anions and cations to spontaneously form nanoparticles; after centrifugation, washing, freeze-drying. The suspension was centrifuged at high speed at 4°C for 20 minut...
PUM
| Property | Measurement | Unit |
|---|---|---|
| particle diameter | aaaaa | aaaaa |
| molecular weight | aaaaa | aaaaa |
| molecular weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 


